肺炎球菌结合疫苗在慢性淋巴细胞白血病患者中比肺炎球菌多糖疫苗触发更好的免疫应答:瑞典慢性淋巴细胞白血病小组的一项随机研究
研究纳入瑞典八家血液科门诊的128例未经治疗的慢性淋巴细胞白血病(CLL)患者,随机接种PCV13(n=63)或PPSV23(n=65)。接种后1个月PCV13在10/12种共同血清型上OPA GMT优于PPSV23,6个月时为5/12种血清型;PPSV23在任何血清型、任何方法或时间点均未优于PCV13。低丙种球蛋白血症和长病程为应答负性预测因素,两种疫苗耐受良好。
要点
- 未经治疗CLL患者中,PCV13在多数共同血清型的免疫应答优于PPSV23。
- 接种后1个月PCV13在10/12血清型OPA GMT更高,6个月为5/12血清型。
- 低丙种球蛋白血症和长病程是疫苗接种应答的负性预测因素。
核心结论
- 在未经治疗的CLL患者中,PCV13在两种疫苗共同的多数血清型上免疫应答优于PPSV23。
- 作者建议将PCV13纳入CLL患者针对肺炎链球菌的疫苗接种计划,并尽可能在病程早期接种。
研究设计与样本
- 随机研究,纳入瑞典八家血液科门诊的128例未经治疗的CLL患者。
- 按IgG水平和CLL临床分期(Rai)分层后随机接种PCV13(n=63)或PPSV23(n=65)。
- 基线和接种后1个月、6个月采血,用OPA和ELISA分析两种疫苗共有的12种肺炎球菌血清型。
主要发现
- 接种后1个月,PCV13在10/12种共同血清型上OPA GMT高于PPSV23;6个月时为5/12种血清型。
- ELISA测定的血清型特异性IgG几何平均浓度,PCV13在1个月和6个月时均在半数共同血清型上高于PPSV23。
- PPSV23在任何血清型、任何分析方法或分析时间点均未比PCV13触发更好的免疫应答。
- 疫苗接种应答的负性预测因素为低丙种球蛋白血症和长病程。
- 两种疫苗均耐受良好。
临床怎么用
- 作者建议将PCV13纳入CLL患者针对肺炎链球菌的疫苗接种计划。
- 作者建议在病程中尽可能早期接种。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: To determine if patients with untreated chronic lymphocytic leukemia (CLL) benefit from vaccination with a 13-valent pneumococcal conjugated vaccine (PCV13), Prevenar13®, compared to a 23-valent pneumococcal polysaccharide vaccine (PPSV23), Pneumovax®, in terms of immune response. BACKGROUND: Streptococcus pneumoniae causes substantial morbidity in patients with CLL, a group known to respond poorly to polysaccharide vaccines. Comparative studies with conjugated vaccines are lacking. METHODS: 128 treatment naïve CLL patients from eight hematology clinics in Sweden were randomized to vaccination with PCV13 (n = 63) or PPSV23 (n = 65) after stratification by IgG level and CLL clinical stage (Rai). Blood samples for evaluation of immune response were obtained at baseline, and at one and six months after vaccination. Analyses for each of the 12 pneumococcal serotypes common for PCV13 and PPSV23 were performed by opsonophagocytic assay (OPA) and enzyme-linked immunosorbent assay (ELISA). RESULTS: PCV13 elicited a superior immune response than PPSV23 in 10/12 serotypes one month after vaccination and in 5/12 serotypes six months after vaccination, measured as OPA geometric mean titers (GMTs). Geometric mean concentrations of serotype-specific IgG antibodies elicited by PCV13 as measured by ELISA, were higher than those elicited by PPSV23 in half of the common serotypes, both after one and six months. PPSV23 did not trigger a better immune response than PCV13 for any of the serotypes, regardless of analysis method or time point of analysis. Negative predictive factors for vaccination response were hypogammaglobulinemia and long disease duration. Both vaccines were well tolerated. CONCLUSIONS: In patients with previously untreated CLL, the efficacy of PCV13 in terms of immune response is superior to PPSV23 for most serotypes common for the two vaccines. We therefore propose that PCV13 should be included in vaccination programs against Streptococcus pneumoniae for CLL patients and administered as early as possible during the course of the disease.
引用
- Svensson T, Kättström M, Hammarlund Y, et al. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group. Vaccine. 2018. PMID: 29748028. doi:10.1016/j.vaccine.2018.05.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。